SG11201701953RA - Detection of misfolded proteins - Google Patents

Detection of misfolded proteins

Info

Publication number
SG11201701953RA
SG11201701953RA SG11201701953RA SG11201701953RA SG11201701953RA SG 11201701953R A SG11201701953R A SG 11201701953RA SG 11201701953R A SG11201701953R A SG 11201701953RA SG 11201701953R A SG11201701953R A SG 11201701953RA SG 11201701953R A SG11201701953R A SG 11201701953RA
Authority
SG
Singapore
Prior art keywords
detection
misfolded proteins
misfolded
proteins
Prior art date
Application number
SG11201701953RA
Other languages
English (en)
Inventor
Claudio Soto Jara
Mohammad Shahnawaz
Russell M Lebovitz
Benedikt K Vollrath
Original Assignee
Univ Texas
Amprion Inc
Claudio Soto Jara
Mohammad Shahnawaz
Russell M Lebovitz
Benedikt K Vollrath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Amprion Inc, Claudio Soto Jara, Mohammad Shahnawaz, Russell M Lebovitz, Benedikt K Vollrath filed Critical Univ Texas
Publication of SG11201701953RA publication Critical patent/SG11201701953RA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
SG11201701953RA 2014-09-11 2015-09-11 Detection of misfolded proteins SG11201701953RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
SG11201701953RA true SG11201701953RA (en) 2017-04-27

Family

ID=55454515

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202008464UA SG10202008464UA (en) 2014-09-11 2015-09-11 Detection of misfolded proteins
SG11201701953RA SG11201701953RA (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202008464UA SG10202008464UA (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Country Status (15)

Country Link
US (1) US20160077112A1 (enExample)
EP (2) EP4292654A3 (enExample)
JP (2) JP6980953B2 (enExample)
KR (1) KR102448128B1 (enExample)
CN (1) CN107208125A (enExample)
AU (1) AU2015314783B2 (enExample)
BR (1) BR112017004899A2 (enExample)
CA (1) CA2960830C (enExample)
ES (1) ES2953855T3 (enExample)
HR (1) HRP20231232T1 (enExample)
IL (2) IL251052B (enExample)
MX (1) MX2017003269A (enExample)
PL (1) PL3191599T3 (enExample)
SG (2) SG10202008464UA (enExample)
WO (1) WO2016040907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040905A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded alpha synuclein protein
GB201611840D0 (en) * 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
WO2018213440A1 (en) * 2017-05-16 2018-11-22 Amprion, Inc. Detection of misfolded tau protein
WO2019070480A1 (en) * 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
EP3729088B1 (en) * 2017-12-21 2021-10-20 H. Lundbeck A/S Diagnosis and treatment of alpha-synucleinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2019222554A2 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of brain injury or neurological disease using tau protein
CA3110200C (en) * 2018-09-21 2023-08-08 Deepmind Technologies Limited Iterative protein structure prediction using gradients of quality scores
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
CA3149743A1 (en) 2019-09-04 2021-03-11 Amprion, Inc. Alpha-synuclein detection using beads
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
KR20230029638A (ko) * 2020-05-18 2023-03-03 암프리온, 인코퍼레이티드 알파-시누클레인 기질 및 이를 제조 및 사용하는 방법
KR20230113574A (ko) * 2020-11-21 2023-07-31 슈원 바이오테크 컴퍼니 리미티드 생물학적 시료 중의 미스폴딩된 단백질을 검출하기 위한 장치 및 방법
WO2022221876A1 (en) * 2021-04-15 2022-10-20 The Brigham And Women's Hospital, Inc. Digital protein misfolding assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60121958T2 (de) 2000-07-07 2007-02-01 Applied Research Systems Ars Holding N.V. Frühdiagnose von konformationellen erkrankungen
EP1366368A2 (en) 2001-01-03 2003-12-03 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
ATE528008T1 (de) * 2006-05-19 2011-10-15 Alnylam Pharmaceuticals Inc Rnai-modulation von aha und ihre therapeutische verwendung
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
WO2011064225A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
US9910049B2 (en) * 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
US20130288389A1 (en) * 2011-01-18 2013-10-31 Prionics Ag Methods for amplification and detection of prions
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof

Also Published As

Publication number Publication date
EP3191599C0 (en) 2023-08-02
IL251052B (en) 2022-05-01
US20160077112A1 (en) 2016-03-17
JP2022000629A (ja) 2022-01-04
JP2017530373A (ja) 2017-10-12
KR102448128B1 (ko) 2022-09-27
CA2960830C (en) 2023-09-05
IL251052A0 (en) 2017-04-30
CA2960830A1 (en) 2016-03-17
EP4292654A2 (en) 2023-12-20
HRP20231232T1 (hr) 2024-01-19
ES2953855T3 (es) 2023-11-16
EP4292654A3 (en) 2024-01-03
EP3191599A4 (en) 2018-03-14
PL3191599T3 (pl) 2023-12-27
MX2017003269A (es) 2017-12-04
EP3191599B1 (en) 2023-08-02
JP6980953B2 (ja) 2021-12-15
IL291809A (en) 2022-06-01
BR112017004899A2 (pt) 2017-12-12
JP7104943B2 (ja) 2022-07-22
AU2015314783B2 (en) 2021-10-21
IL291809B2 (en) 2023-06-01
CN107208125A (zh) 2017-09-26
WO2016040907A1 (en) 2016-03-17
SG10202008464UA (en) 2020-10-29
KR20170103741A (ko) 2017-09-13
EP3191599A1 (en) 2017-07-19
AU2015314783A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
IL291809B2 (en) Detection of unfolded proteins
IL240153B (en) Line of block detection
GB2537553B (en) Proximity detection
ZA201606987B (en) Methods and compositions for detecting misfolded proteins
SG11201607796TA (en) Nanopore-based analysis of protein characteristics
GB2545480B (en) Detection of coordinated cyber-attacks
GB201415344D0 (en) Protein
PL3099791T3 (pl) Białko
SG11201610430QA (en) Growth-independent detection of cells
PL3099793T3 (pl) Białko
GB201417384D0 (en) Detection of polymyxins
GB201518675D0 (en) Detection of structural forms of proteins
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
GB201411568D0 (en) Detection
HK40092181A (zh) 检测错误折叠蛋白的方法和组合物
GB201403310D0 (en) Polypeptide detection
GB201504021D0 (en) Detection of one or more tissue derived aggretated proteins
GB201412797D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201405955D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201403915D0 (en) Proteins